Global Mitral Regurgitation Market
Global Mitral Regurgitation Market

Mitral Regurgitation Comprehensive Study by Type (Chronic, Acute), Treatment (Mitral Valve Repair, Medical Therapy, Mitral Valve Replacement, Anticoagulants, Angiotensin-Converting Enzyme (ACE) Inhibitors), End-User (Hospitals, Cardiac Catheterization Laboratory, Surgical Ambulatory Services), Diagnosis (Physical Examination, Echocardiography, ECG) Players and Region - Global Market Outlook to 2027

Mitral Regurgitation Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Feb 2022 Edition 250 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Mitral Regurgitation Market Overview:
Mitral regurgitation (MR) is a condition in which the mitral valve becomes ineffective, allowing flow from the left ventricle (LV) into the left atrium during ventricular systole. MR can be caused by either LV dilation or infarction. Progression of heart failure, arrhythmias, and endocarditis are all possible complications. Patients with mild, asymptomatic MR can be monitored, but patients with progressive or symptomatic MR need mitral valve repair or replacement. Minimally or non-invasive therapies, as well as many other techniques, are currently in development for patients who are at high risk or inoperable. This technological advancement provides cardiac surgeons and interventional cardiologists with new ways to meet the needs of their patients. The growing prevalence of heart disease expands the patient pool, increasing the demand for better treatment and novel products.

Growth Drivers
  • Rising Number of Heart Diseases Heart
  • Increase in Mitral Valve Disorders

Roadblocks
  • Stringent Regulations by the Governing Bodies
  • High Cost of Mitral Regurgitation Surgery

Opportunities
  • Rising Technological Advancements

Challenges
  • High Risk of Side Effects of Treatment
  • Availability of Low-Cost Counterfeit Products


Competitive Landscape:
The demand for Mitral Regurgitation is increasing. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position. Players are expected to focus on the creation of new compounds, which would likely drive the worldwide market forward over the forecast period.
Some of the key players profiled in the report are Abbott Laboratories (United States), Edwards Lifesciences (United States), Cedars-Sinai Medical Center (United States), Stanford Health Care (United States), Beaumont Health (United States), Neovasc Inc. (Canada), LivaNova PLC (United Kingdom), Boston Scientific (United States), Geisinger (United States) and Venus MedTech HangZhou Inc (China). Additionally, following companies can also be profiled that are part of our coverage like Cardiac Dimensions (United States), Affluent Medical (France) and Coramaze Technologies (Germany). Analyst at AMA Research see United States Players to retain maximum share of Global Mitral Regurgitation market by 2027. Considering Market by Treatment, the sub-segment i.e. Mitral Valve Repair will boost the Mitral Regurgitation market. Considering Market by End-User, the sub-segment i.e. Hospitals will boost the Mitral Regurgitation market. Considering Market by Diagnosis, the sub-segment i.e. Physical Examination will boost the Mitral Regurgitation market.

In October 2020 Medtronic had announced partnership with The Foundry to develop Mitral Valve Repair Technology. The collaboration combines Medtronic’s structural heart and intellectual property with The Foundry's innovation in transcatheter mitral valve repair and replacement.

What Can be Explored with the Mitral Regurgitation Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Mitral Regurgitation Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Mitral Regurgitation
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Mitral Regurgitation market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Mitral Regurgitation market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Mitral Regurgitation Market?
The Mitral Regurgitation market is expected to see a CAGR of % during projected year 2021 to 2027.

2. Who are the top performing companies in Mitral Regurgitation Market?
Top performing companies in the Global Mitral Regurgitation market are Abbott Laboratories (United States), Edwards Lifesciences (United States), Cedars-Sinai Medical Center (United States), Stanford Health Care (United States), Beaumont Health (United States), Neovasc Inc. (Canada), LivaNova PLC (United Kingdom), Boston Scientific (United States), Geisinger (United States) and Venus MedTech HangZhou Inc (China), to name a few.

3. What trending factors would impact Mitral Regurgitation Market growth most?
"Advent of Novel Mitral Valves " is seen as one of major influencing trends for Mitral Regurgitation Market during projected period 2021-2027.

Report Objectives / Segmentation Covered
By Type
  • Chronic
  • Acute
By Treatment
  • Mitral Valve Repair
  • Medical Therapy
  • Mitral Valve Replacement
  • Anticoagulants
  • Angiotensin-Converting Enzyme (ACE) Inhibitors

By End-User
  • Hospitals
  • Cardiac Catheterization Laboratory
  • Surgical Ambulatory Services

By Diagnosis
  • Physical Examination
  • Echocardiography
  • ECG

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Heart Diseases Heart
      • 3.2.2. Increase in Mitral Valve Disorders
    • 3.3. Market Challenges
      • 3.3.1. High Risk of Side Effects of Treatment
      • 3.3.2. Availability of Low-Cost Counterfeit Products
    • 3.4. Market Trends
      • 3.4.1. Advent of Novel Mitral Valves
      • 3.4.2. Growing Adoption of Non-Invasive Transcatheter Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mitral Regurgitation, by Type, Treatment, End-User, Diagnosis and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Mitral Regurgitation (Value)
      • 5.2.1. Global Mitral Regurgitation by: Type (Value)
        • 5.2.1.1. Chronic
        • 5.2.1.2. Acute
      • 5.2.2. Global Mitral Regurgitation by: Treatment (Value)
        • 5.2.2.1. Mitral Valve Repair
        • 5.2.2.2. Medical Therapy
        • 5.2.2.3. Mitral Valve Replacement
        • 5.2.2.4. Anticoagulants
        • 5.2.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
      • 5.2.3. Global Mitral Regurgitation by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cardiac Catheterization Laboratory
        • 5.2.3.3. Surgical Ambulatory Services
      • 5.2.4. Global Mitral Regurgitation by: Diagnosis (Value)
        • 5.2.4.1. Physical Examination
        • 5.2.4.2. Echocardiography
        • 5.2.4.3. ECG
      • 5.2.5. Global Mitral Regurgitation Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Mitral Regurgitation (Price)
      • 5.3.1. Global Mitral Regurgitation by: Type (Price)
  • 6. Mitral Regurgitation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Edwards Lifesciences (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cedars-Sinai Medical Center (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Stanford Health Care (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Beaumont Health (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Neovasc Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LivaNova PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boston Scientific (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Geisinger (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Venus MedTech HangZhou Inc (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mitral Regurgitation Sale, by Type, Treatment, End-User, Diagnosis and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Mitral Regurgitation (Value)
      • 7.2.1. Global Mitral Regurgitation by: Type (Value)
        • 7.2.1.1. Chronic
        • 7.2.1.2. Acute
      • 7.2.2. Global Mitral Regurgitation by: Treatment (Value)
        • 7.2.2.1. Mitral Valve Repair
        • 7.2.2.2. Medical Therapy
        • 7.2.2.3. Mitral Valve Replacement
        • 7.2.2.4. Anticoagulants
        • 7.2.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
      • 7.2.3. Global Mitral Regurgitation by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cardiac Catheterization Laboratory
        • 7.2.3.3. Surgical Ambulatory Services
      • 7.2.4. Global Mitral Regurgitation by: Diagnosis (Value)
        • 7.2.4.1. Physical Examination
        • 7.2.4.2. Echocardiography
        • 7.2.4.3. ECG
      • 7.2.5. Global Mitral Regurgitation Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Mitral Regurgitation (Price)
      • 7.3.1. Global Mitral Regurgitation by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mitral Regurgitation: by Type(USD Million)
  • Table 2. Mitral Regurgitation Chronic , by Region USD Million (2016-2021)
  • Table 3. Mitral Regurgitation Acute , by Region USD Million (2016-2021)
  • Table 4. Mitral Regurgitation: by Treatment(USD Million)
  • Table 5. Mitral Regurgitation Mitral Valve Repair , by Region USD Million (2016-2021)
  • Table 6. Mitral Regurgitation Medical Therapy , by Region USD Million (2016-2021)
  • Table 7. Mitral Regurgitation Mitral Valve Replacement , by Region USD Million (2016-2021)
  • Table 8. Mitral Regurgitation Anticoagulants , by Region USD Million (2016-2021)
  • Table 9. Mitral Regurgitation Angiotensin-Converting Enzyme (ACE) Inhibitors , by Region USD Million (2016-2021)
  • Table 10. Mitral Regurgitation: by End-User(USD Million)
  • Table 11. Mitral Regurgitation Hospitals , by Region USD Million (2016-2021)
  • Table 12. Mitral Regurgitation Cardiac Catheterization Laboratory , by Region USD Million (2016-2021)
  • Table 13. Mitral Regurgitation Surgical Ambulatory Services , by Region USD Million (2016-2021)
  • Table 14. Mitral Regurgitation: by Diagnosis(USD Million)
  • Table 15. Mitral Regurgitation Physical Examination , by Region USD Million (2016-2021)
  • Table 16. Mitral Regurgitation Echocardiography , by Region USD Million (2016-2021)
  • Table 17. Mitral Regurgitation ECG , by Region USD Million (2016-2021)
  • Table 18. South America Mitral Regurgitation, by Country USD Million (2016-2021)
  • Table 19. South America Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 20. South America Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 21. South America Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 22. South America Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 23. Brazil Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 24. Brazil Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 25. Brazil Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 26. Brazil Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 27. Argentina Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 28. Argentina Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 29. Argentina Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 30. Argentina Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 31. Rest of South America Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 32. Rest of South America Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 33. Rest of South America Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 34. Rest of South America Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 35. Asia Pacific Mitral Regurgitation, by Country USD Million (2016-2021)
  • Table 36. Asia Pacific Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 37. Asia Pacific Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 38. Asia Pacific Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 39. Asia Pacific Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 40. China Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 41. China Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 42. China Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 43. China Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 44. Japan Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 45. Japan Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 46. Japan Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 47. Japan Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 48. India Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 49. India Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 50. India Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 51. India Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 52. South Korea Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 53. South Korea Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 54. South Korea Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 55. South Korea Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 56. Taiwan Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 57. Taiwan Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 58. Taiwan Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 59. Taiwan Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 60. Australia Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 61. Australia Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 62. Australia Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 63. Australia Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 68. Europe Mitral Regurgitation, by Country USD Million (2016-2021)
  • Table 69. Europe Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 70. Europe Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 71. Europe Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 72. Europe Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 73. Germany Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 74. Germany Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 75. Germany Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 76. Germany Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 77. France Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 78. France Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 79. France Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 80. France Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 81. Italy Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 82. Italy Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 83. Italy Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 84. Italy Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 85. United Kingdom Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 86. United Kingdom Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 87. United Kingdom Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 88. United Kingdom Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 89. Netherlands Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 90. Netherlands Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 91. Netherlands Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 92. Netherlands Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 93. Rest of Europe Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 94. Rest of Europe Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 95. Rest of Europe Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 96. Rest of Europe Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 97. MEA Mitral Regurgitation, by Country USD Million (2016-2021)
  • Table 98. MEA Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 99. MEA Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 100. MEA Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 101. MEA Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 102. Middle East Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 103. Middle East Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 104. Middle East Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 105. Middle East Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 106. Africa Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 107. Africa Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 108. Africa Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 109. Africa Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 110. North America Mitral Regurgitation, by Country USD Million (2016-2021)
  • Table 111. North America Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 112. North America Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 113. North America Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 114. North America Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 115. United States Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 116. United States Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 117. United States Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 118. United States Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 119. Canada Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 120. Canada Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 121. Canada Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 122. Canada Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 123. Mexico Mitral Regurgitation, by Type USD Million (2016-2021)
  • Table 124. Mexico Mitral Regurgitation, by Treatment USD Million (2016-2021)
  • Table 125. Mexico Mitral Regurgitation, by End-User USD Million (2016-2021)
  • Table 126. Mexico Mitral Regurgitation, by Diagnosis USD Million (2016-2021)
  • Table 127. Mitral Regurgitation: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Mitral Regurgitation: by Type(USD Million)
  • Table 139. Mitral Regurgitation Chronic , by Region USD Million (2022-2027)
  • Table 140. Mitral Regurgitation Acute , by Region USD Million (2022-2027)
  • Table 141. Mitral Regurgitation: by Treatment(USD Million)
  • Table 142. Mitral Regurgitation Mitral Valve Repair , by Region USD Million (2022-2027)
  • Table 143. Mitral Regurgitation Medical Therapy , by Region USD Million (2022-2027)
  • Table 144. Mitral Regurgitation Mitral Valve Replacement , by Region USD Million (2022-2027)
  • Table 145. Mitral Regurgitation Anticoagulants , by Region USD Million (2022-2027)
  • Table 146. Mitral Regurgitation Angiotensin-Converting Enzyme (ACE) Inhibitors , by Region USD Million (2022-2027)
  • Table 147. Mitral Regurgitation: by End-User(USD Million)
  • Table 148. Mitral Regurgitation Hospitals , by Region USD Million (2022-2027)
  • Table 149. Mitral Regurgitation Cardiac Catheterization Laboratory , by Region USD Million (2022-2027)
  • Table 150. Mitral Regurgitation Surgical Ambulatory Services , by Region USD Million (2022-2027)
  • Table 151. Mitral Regurgitation: by Diagnosis(USD Million)
  • Table 152. Mitral Regurgitation Physical Examination , by Region USD Million (2022-2027)
  • Table 153. Mitral Regurgitation Echocardiography , by Region USD Million (2022-2027)
  • Table 154. Mitral Regurgitation ECG , by Region USD Million (2022-2027)
  • Table 155. South America Mitral Regurgitation, by Country USD Million (2022-2027)
  • Table 156. South America Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 157. South America Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 158. South America Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 159. South America Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 160. Brazil Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 161. Brazil Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 162. Brazil Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 163. Brazil Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 164. Argentina Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 165. Argentina Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 166. Argentina Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 167. Argentina Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 168. Rest of South America Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 169. Rest of South America Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 170. Rest of South America Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 171. Rest of South America Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 172. Asia Pacific Mitral Regurgitation, by Country USD Million (2022-2027)
  • Table 173. Asia Pacific Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 174. Asia Pacific Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 175. Asia Pacific Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 176. Asia Pacific Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 177. China Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 178. China Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 179. China Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 180. China Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 181. Japan Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 182. Japan Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 183. Japan Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 184. Japan Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 185. India Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 186. India Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 187. India Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 188. India Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 189. South Korea Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 190. South Korea Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 191. South Korea Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 192. South Korea Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 193. Taiwan Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 194. Taiwan Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 195. Taiwan Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 196. Taiwan Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 197. Australia Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 198. Australia Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 199. Australia Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 200. Australia Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 204. Rest of Asia-Pacific Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 205. Europe Mitral Regurgitation, by Country USD Million (2022-2027)
  • Table 206. Europe Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 207. Europe Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 208. Europe Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 209. Europe Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 210. Germany Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 211. Germany Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 212. Germany Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 213. Germany Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 214. France Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 215. France Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 216. France Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 217. France Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 218. Italy Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 219. Italy Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 220. Italy Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 221. Italy Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 222. United Kingdom Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 223. United Kingdom Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 224. United Kingdom Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 225. United Kingdom Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 226. Netherlands Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 227. Netherlands Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 228. Netherlands Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 229. Netherlands Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 230. Rest of Europe Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 231. Rest of Europe Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 232. Rest of Europe Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 233. Rest of Europe Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 234. MEA Mitral Regurgitation, by Country USD Million (2022-2027)
  • Table 235. MEA Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 236. MEA Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 237. MEA Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 238. MEA Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 239. Middle East Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 240. Middle East Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 241. Middle East Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 242. Middle East Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 243. Africa Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 244. Africa Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 245. Africa Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 246. Africa Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 247. North America Mitral Regurgitation, by Country USD Million (2022-2027)
  • Table 248. North America Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 249. North America Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 250. North America Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 251. North America Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 252. United States Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 253. United States Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 254. United States Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 255. United States Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 256. Canada Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 257. Canada Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 258. Canada Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 259. Canada Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 260. Mexico Mitral Regurgitation, by Type USD Million (2022-2027)
  • Table 261. Mexico Mitral Regurgitation, by Treatment USD Million (2022-2027)
  • Table 262. Mexico Mitral Regurgitation, by End-User USD Million (2022-2027)
  • Table 263. Mexico Mitral Regurgitation, by Diagnosis USD Million (2022-2027)
  • Table 264. Mitral Regurgitation: by Type(USD/Units)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mitral Regurgitation: by Type USD Million (2016-2021)
  • Figure 5. Global Mitral Regurgitation: by Treatment USD Million (2016-2021)
  • Figure 6. Global Mitral Regurgitation: by End-User USD Million (2016-2021)
  • Figure 7. Global Mitral Regurgitation: by Diagnosis USD Million (2016-2021)
  • Figure 8. South America Mitral Regurgitation Share (%), by Country
  • Figure 9. Asia Pacific Mitral Regurgitation Share (%), by Country
  • Figure 10. Europe Mitral Regurgitation Share (%), by Country
  • Figure 11. MEA Mitral Regurgitation Share (%), by Country
  • Figure 12. North America Mitral Regurgitation Share (%), by Country
  • Figure 13. Global Mitral Regurgitation: by Type USD/Units (2016-2021)
  • Figure 14. Global Mitral Regurgitation share by Players 2021 (%)
  • Figure 15. Global Mitral Regurgitation share by Players (Top 3) 2021(%)
  • Figure 16. Global Mitral Regurgitation share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 20. Edwards Lifesciences (United States) Revenue, Net Income and Gross profit
  • Figure 21. Edwards Lifesciences (United States) Revenue: by Geography 2021
  • Figure 22. Cedars-Sinai Medical Center (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cedars-Sinai Medical Center (United States) Revenue: by Geography 2021
  • Figure 24. Stanford Health Care (United States) Revenue, Net Income and Gross profit
  • Figure 25. Stanford Health Care (United States) Revenue: by Geography 2021
  • Figure 26. Beaumont Health (United States) Revenue, Net Income and Gross profit
  • Figure 27. Beaumont Health (United States) Revenue: by Geography 2021
  • Figure 28. Neovasc Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Neovasc Inc. (Canada) Revenue: by Geography 2021
  • Figure 30. LivaNova PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. LivaNova PLC (United Kingdom) Revenue: by Geography 2021
  • Figure 32. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 33. Boston Scientific (United States) Revenue: by Geography 2021
  • Figure 34. Geisinger (United States) Revenue, Net Income and Gross profit
  • Figure 35. Geisinger (United States) Revenue: by Geography 2021
  • Figure 36. Venus MedTech HangZhou Inc (China) Revenue, Net Income and Gross profit
  • Figure 37. Venus MedTech HangZhou Inc (China) Revenue: by Geography 2021
  • Figure 38. Global Mitral Regurgitation: by Type USD Million (2022-2027)
  • Figure 39. Global Mitral Regurgitation: by Treatment USD Million (2022-2027)
  • Figure 40. Global Mitral Regurgitation: by End-User USD Million (2022-2027)
  • Figure 41. Global Mitral Regurgitation: by Diagnosis USD Million (2022-2027)
  • Figure 42. South America Mitral Regurgitation Share (%), by Country
  • Figure 43. Asia Pacific Mitral Regurgitation Share (%), by Country
  • Figure 44. Europe Mitral Regurgitation Share (%), by Country
  • Figure 45. MEA Mitral Regurgitation Share (%), by Country
  • Figure 46. North America Mitral Regurgitation Share (%), by Country
  • Figure 47. Global Mitral Regurgitation: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Edwards Lifesciences (United States)
  • Cedars-Sinai Medical Center (United States)
  • Stanford Health Care (United States)
  • Beaumont Health (United States)
  • Neovasc Inc. (Canada)
  • LivaNova PLC (United Kingdom)
  • Boston Scientific (United States)
  • Geisinger (United States)
  • Venus MedTech HangZhou Inc (China)
Additional players considered in the study are as follows:
Cardiac Dimensions (United States) , Affluent Medical (France) , Coramaze Technologies (Germany) ,
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation